We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Mereo BioPharma Group PLC | NASDAQ:MREO | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.12 | 3.75% | 3.32 | 3.23 | 3.32 | 3.34 | 3.135 | 3.20 | 445,696 | 22:37:07 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 or 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2019
Commission File Number: 001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrants name into English)
4 th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐
Mereo BioPharma Group plc
Holding(s) in Company
London, July 8, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today provided a regulatory news service (RNS) notification of major holdings through the London Stock Exchange plc, a copy of which is provided below.
RNS Number : 8439E
Mereo BioPharma Group plc
08 July 2019
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible) i
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached ii :
|
Mereo Biopharma Group PLC
|
|
1b. Please indicate if the issuer is a non-UK issuer (please mark with an X if appropriate)
|
Non-UK issuer
|
||
2. Reason for the notification (please mark the appropriate box or boxes with an X)
|
An acquisition or disposal of voting rights
|
||
An acquisition or disposal of financial instruments
|
||
An event changing the breakdown of voting rights
|
||
Other (please
specify)
iii
:
|
X |
% of voting rights attached to shares (total of 8. A) |
% of voting rights through financial instruments
|
Total of both in % (8.A + 8.B) |
Total number of voting rights of issuer vii |
Resulting situation on the date on which threshold was crossed or reached
|
27.56% | 27.56% | 97,959,622 | |||||
Position of previous notification (if applicable)
|
30.46% | 30.46% |
9. Information in relation to the person subject to the notification obligation (please mark the applicable box with an X) |
||||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer xiii | X | |||||
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entity xiv (please add additional rows as necessary) |
Name xv |
% of voting rights if it equals or is higher than the notifiable threshold |
% of voting rights through financial instruments if it equals or is higher than the notifiable threshold |
Total of both if it equals or is higher than the notifiable threshold |
|||
Woodford Investment Management Ltd | 27.56 | 0.00 | 27.56 |
10. In case of proxy voting, please identify: | ||||||
Name of the proxy holder |
||||||
The number and % of voting rights held |
||||||
The date until which the voting rights will be held |
11. Additional information xvi |
||||||
Place of completion
|
9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
|
|||||
Date of completion
|
08/07/2019
|
Further Enquiries
Mereo | +44 (0)333 023 7300 | |||
Denise Scots-Knight, Chief Executive Officer | ||||
Richard Jones, Chief Financial Officer | ||||
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo ) | +44 (0)20 7894 7000 | |||
Phil Davies | ||||
Will Goode | ||||
RBC Capital Markets (Joint Broker to Mereo ) | +44 (0)20 7653 4000 | |||
Rupert Walford | ||||
Jamil Miah | ||||
FTI Consulting (Public Relations Adviser to Mereo ) | ||||
Simon Conway | +44 (0)20 3727 1000 | |||
Brett Pollard | ||||
Ciara Martin | ||||
Burns McClellan (US Public Relations Adviser to Mereo ) | +01 (0) 212 213 0006 | |||
Lisa Burns | ||||
Steve Klass |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 8, 2019
MEREO BIOPHARMA GROUP PLC | ||
By: |
/s/ Charles Sermon |
|
Name: | Charles Sermon | |
Title: | General Counsel |
1 Year Mereo BioPharma Chart |
1 Month Mereo BioPharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions